Successful treatment of refractory prurigo nodularis with baricitinib
Author:
Affiliation:
1. Zunyi Medical University Zunyi China
2. Department of Dermatology Peking University Shenzhen Hospital Shenzhen China
3. Shantou University Medical College Shantou China
Publisher
Hindawi Limited
Subject
Dermatology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15642
Reference10 articles.
1. Prurigo nodularis
2. The pathogenesis of Prurigo nodularis - ‘Super-Itch’ in exploration
3. Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis
4. Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options
5. Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Successful treatment of prurigo nodularis with abrocitinib: A case report;Dermatologica Sinica;2024-08-19
2. Abrocitinib Monotherapy for Refractory Prurigo Nodularis: Report of Two Successful Cases;Clinical, Cosmetic and Investigational Dermatology;2024-08
3. Pruritus in the Elderly: Differential Diagnosis and Management;Current Geriatrics Reports;2024-05-23
4. Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics;International Journal of Molecular Sciences;2024-05-09
5. Baricitinib for Prurigo Nodularis: A Pilot Study on Efficacy and Safety;Dermatologic Therapy;2024-05-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3